Molecular Imaging of Primary Amyloid Cardiomyopathy

Summary

Cardiac amyloidosis is a major cause of early treatment-related death and poor overall survival in individuals with systemic light chain amyloidosis. This project will develop a novel approach to visualize cardiac amyloid deposits using advanced imaging methods. The long-term goal of this work is to identify the mechanisms of cardiac dysfunction, in order to guide the development of novel life-saving treatments.

Conditions

• Amyloidosis, Primary
• Cardiomyopathy

Interventions

RADIATION

F-18 florbetapir/C-11 acetate PET

F-18 florbetapir PET scan, C-11 acetate PET scan

DEVICE

MRI

Cardiac MRI with gadolinium contrast.

RADIATION

N-13 ammonia PET

N-13 ammonia PET scan following supine bicycle stress.

Sponsors & Collaborators

• National Institutes of Health (NIH)

  collaborator NIH

• National Heart, Lung, and Blood Institute (NHLBI)

  collaborator NIH

• American Heart Association

  collaborator OTHER

• Brigham and Women's Hospital

  lead OTHER

Principal Investigators

• Sharmila Dorbala, MD · Brigham and Women's Hospital (AHA and NIH Studies)

• Rodney Falk, MD · Brigham and Women's Hospital (NIH Study)

• Ronglih Liao, PhD · Stanford School of Medicine (AHA Study)

Study Design

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Max Age

99 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2016-04-01

Primary Completion

2027-12-31

Completion

2028-12-31

Countries

• United States

Study Locations